At the time of writing, Rhythm Pharmaceuticals Inc [RYTM] stock is trading at $55.21, up 5.58%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The RYTM shares have gain 7.58% over the last week, with a monthly amount drifted -4.07%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Previously, Jefferies started tracking the stock with Buy rating on January 02, 2025, and set its price target to $80. On December 20, 2024, Oppenheimer initiated with a Outperform rating and assigned a price target of $76 on the stock. Guggenheim started tracking the stock assigning a Buy rating and suggested a price target of $70 on October 21, 2024. H.C. Wainwright initiated its recommendation with a Buy and recommended $64 as its price target on September 18, 2024. JMP Securities started tracking with a Mkt Outperform rating for this stock on September 17, 2024, and assigned it a price target of $64. In a note dated May 08, 2024, BofA Securities downgraded an Neutral rating on this stock and revised its target price from $49 to $42.
For the past year, the stock price of Rhythm Pharmaceuticals Inc fluctuated between $35.17 and $68.58. Currently, Wall Street analysts expect the stock to reach $71.6 within the next 12 months. Rhythm Pharmaceuticals Inc [NASDAQ: RYTM] shares were valued at $55.21 at the most recent close of the market. An investor can expect a potential return of 29.69% based on the average RYTM price forecast.
Analyzing the RYTM fundamentals
According to Rhythm Pharmaceuticals Inc [NASDAQ:RYTM], the company’s sales were 130.13M for trailing twelve months, which represents an 72.61% jump. Gross Profit Margin for this corporation currently stands at 0.89% with Operating Profit Margin at -2.04%, Pretax Profit Margin comes in at -2.0%, and Net Profit Margin reading is -2.01%. To continue investigating profitability, this company’s Return on Assets is posted at -0.67, Equity is -3.79 and Total Capital is -0.96. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.02.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 52.95 points at the first support level, and at 50.69 for the second support level. However, for the 1st resistance point, the stock is sitting at 56.67, and for the 2nd resistance point, it is at 58.13.
Ratios To Look Out For
It is important to note that Rhythm Pharmaceuticals Inc [NASDAQ:RYTM] has a current ratio of 3.24. As well, the Quick Ratio is 3.08, while the Cash Ratio is 0.77. Considering the valuation of this stock, the price to sales ratio is 26.82, the price to book ratio is 158.53.
Transactions by insiders
Recent insider trading involved Mazabraud Yann, EVP, Head of International, that happened on Mar 14 ’25 when 75000.0 shares were sold. Officer, YANN MAZZABRAUD completed a deal on Mar 14 ’25 to buy 75000.0 shares. Meanwhile, Chief Financial Officer Smith Hunter C sold 2215.0 shares on Feb 19 ’25.
